Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.
For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.
Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect